Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Trademark and unfair competition matters for Pfizer Inc.
Represents Pfizer Inc., one of the world's largest pharmaceutical companies, in trademark and unfair competition matters, including litigation before more
Advice on laws impacting health and welfare plans for a leading cancer health organization
Counsel a leading cancer health organization on federal laws impacting group health and welfare plans. more
Obtaining various regulatory exemptions for a benefits payment services company
Represented a benefits payment services company in obtaining exemptions from the HIPAA electronic transaction rule. more
Real estate and construction consultation to Kane Realty on a continuing care retirement community project
Represented Kane Realty as a joint venture partner involved in the development and construction of a continuing care retirement community (CCRC), more